A Phase I Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmacokinetic Trial of BNT331 Administered in Single Ascending Doses in Healthy Women and Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis
Latest Information Update: 26 Aug 2025
At a glance
- Drugs BNT 331 (Primary)
- Indications Bacterial vaginosis
- Focus Adverse reactions; First in man
- Sponsors BioNTech
Most Recent Events
- 07 Aug 2025 Status changed from active, no longer recruiting to completed.
- 17 Apr 2025 Planned End Date changed from 1 Jun 2025 to 1 Aug 2025.
- 17 Apr 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Aug 2025.